These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31992509)

  • 1. Transient elastography for assessment of fibrosis and steatosis of liver grafts from brain-death donors.
    Liu WY; Wang JH; Guo Y; Wang X; Wu XD; Xu CS; Zhao Y; Zang YJ
    Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):155-161. PubMed ID: 31992509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inverse effect of meal intake on controlled attenuation parameter and liver stiffness as assessed by transient elastography.
    Ratchatasettakul K; Rattanasiri S; Promson K; Sringam P; Sobhonslidsuk A
    BMC Gastroenterol; 2017 Apr; 17(1):50. PubMed ID: 28407734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
    de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
    Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasound and FibroScan
    Salmi A; di Filippo L; Ferrari C; Frara S; Giustina A
    Endocrine; 2022 Nov; 78(2):262-269. PubMed ID: 35980569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
    Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
    Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled Attenuation Parameter and Liver Stiffness Measurements for Steatosis Assessment in the Liver Transplant of Brain Dead Donors.
    Mancia C; Loustaud-Ratti V; Carrier P; Naudet F; Bellissant E; Labrousse F; Pichon N
    Transplantation; 2015 Aug; 99(8):1619-24. PubMed ID: 25719261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: a prospective study.
    Lupșor-Platon M; Feier D; Stefănescu H; Tamas A; Botan E; Sparchez Z; Maniu A; Badea R
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):35-42. PubMed ID: 25822432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis?
    Trowell J; Alukal J; Zhang T; Liu L; Maheshwari A; Yoo HY; Thuluvath PJ
    Dig Dis Sci; 2021 Apr; 66(4):1297-1305. PubMed ID: 32337667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.
    Park CC; Nguyen P; Hernandez C; Bettencourt R; Ramirez K; Fortney L; Hooker J; Sy E; Savides MT; Alquiraish MH; Valasek MA; Rizo E; Richards L; Brenner D; Sirlin CB; Loomba R
    Gastroenterology; 2017 Feb; 152(3):598-607.e2. PubMed ID: 27911262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B.
    Cardoso AC; Beaugrand M; de Ledinghen V; Douvin C; Poupon R; Trinchet JC; Ziol M; Bedossa P; Marcellin P
    Ann Hepatol; 2015; 14(6):826-36. PubMed ID: 26436354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B.
    Wang CY; Lu W; Hu DS; Wang GD; Cheng XJ
    World J Gastroenterol; 2014 Aug; 20(30):10585-90. PubMed ID: 25132779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy.
    Yilmaz Y; Yesil A; Gerin F; Ergelen R; Akin H; Celikel ÇA; Imeryuz N
    Scand J Gastroenterol; 2014 May; 49(5):611-6. PubMed ID: 24611771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease.
    Lee HA; Kim SS; Choi JY; Seo YS; Park BJ; Sim KC; Kim SU
    Abdom Radiol (NY); 2022 Nov; 47(11):3733-3745. PubMed ID: 35962809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
    Siddiqui MS; Vuppalanchi R; Van Natta ML; Hallinan E; Kowdley KV; Abdelmalek M; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Brandman D; Doo E; Tonascia JA; Kleiner DE; Chalasani N; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):156-163.e2. PubMed ID: 29705261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
    de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
    J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.
    Semmler G; Wöran K; Scheiner B; Unger LW; Paternostro R; Stift J; Schwabl P; Bucsics T; Bauer D; Simbrunner B; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
    United European Gastroenterol J; 2020 Apr; 8(3):321-331. PubMed ID: 32213023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.